Armand Abergel1, Michel Rotily2, Sébastien Branchoux3, Raoudha Akremi4, Lucie de Léotoing5, Alexandre Vainchtock5, Anne-Françoise Gaudin6. 1. Department of Digestive Medicine, CHU Estaing, Clermont-Ferrand, France; Unité mixte de recherche Université d'Auvergne CNRS 6284, France. 2. Department of Geriatric Medicine, Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France. 3. Health Economics and Outcomes Research, Laboratoire Bristol-Myers Squibb, 3, rue Joseph-Monier, 92500 Rueil-Malmaison, France. Electronic address: sebastien.branchoux@bms.com. 4. Medical Affairs, Laboratoire Bristol-Myers Squibb, 3, rue Joseph-Monier, 92500 Rueil-Malmaison, France. 5. HEVA, Lyon, France. 6. Health Economics and Outcomes Research, Laboratoire Bristol-Myers Squibb, 3, rue Joseph-Monier, 92500 Rueil-Malmaison, France.
Abstract
BACKGROUND AND OBJECTIVE: This retrospective hospital database analysis aimed to determine the burden and cost of hospitalisations related to chronic hepatitis C (CHC) infections in France in 2012. METHODS: All hospital stays with CHC (ICD-10 code B18.2) coded as the principal, related or significantly associated diagnosis were extracted from the French National Hospital database 2012 (PMSI). Hospitalisations not directly related to CHC were excluded. Patients were assigned to a liver disease stage, namely non-cirrhotic liver disease, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma or post-liver transplantation. Costing was performed using French national tariffs and expressed in 2013 Euros. We documented 22,056 hospital stays involving 12,040 patients who were considered to be directly related to CHC. Of these stays, 11,779 (53.4%) were documented in patients with severe complications (decompensated cirrhosis, hepatocellular carcinoma or liver transplantation). RESULTS AND CONCLUSIONS: The mean number and duration of hospital stays increased with disease severity. Overall, 1181 patients (9.8%) died during hospitalisation. The total cost of hospital stays for CHC was estimated to be € 61 million, of which 26.4% were attributable to hepatocellular carcinoma, 32.5% to post-liver transplantation and 21.0% to decompensated cirrhosis. Compared with a previous analysis in 2009, the number of patients hospitalised fell by 22%, although the patients hospitalised were overall more severely ill. The total cost of hospitalisation decreased by 8%, with a notably marked reduction in the number of biopsies performed (32%). This study illustrates the persistently high burden of CHC infections in France.
BACKGROUND AND OBJECTIVE: This retrospective hospital database analysis aimed to determine the burden and cost of hospitalisations related to chronic hepatitis C (CHC) infections in France in 2012. METHODS: All hospital stays with CHC (ICD-10 code B18.2) coded as the principal, related or significantly associated diagnosis were extracted from the French National Hospital database 2012 (PMSI). Hospitalisations not directly related to CHC were excluded. Patients were assigned to a liver disease stage, namely non-cirrhotic liver disease, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma or post-liver transplantation. Costing was performed using French national tariffs and expressed in 2013 Euros. We documented 22,056 hospital stays involving 12,040 patients who were considered to be directly related to CHC. Of these stays, 11,779 (53.4%) were documented in patients with severe complications (decompensated cirrhosis, hepatocellular carcinoma or liver transplantation). RESULTS AND CONCLUSIONS: The mean number and duration of hospital stays increased with disease severity. Overall, 1181 patients (9.8%) died during hospitalisation. The total cost of hospital stays for CHC was estimated to be € 61 million, of which 26.4% were attributable to hepatocellular carcinoma, 32.5% to post-liver transplantation and 21.0% to decompensated cirrhosis. Compared with a previous analysis in 2009, the number of patients hospitalised fell by 22%, although the patients hospitalised were overall more severely ill. The total cost of hospitalisation decreased by 8%, with a notably marked reduction in the number of biopsies performed (32%). This study illustrates the persistently high burden of CHC infections in France.
Authors: John Chen Hsiang; Pream Sinnaswami; Mui Yok Lee; Meng Meng Zhang; Kwang Ee Quek; Keng Hwee Tan; Yew Meng Wong; Prem Harichander Thurairajah Journal: Singapore Med J Date: 2020-07-30 Impact factor: 3.331
Authors: Young-Hwan Ahn; Heirim Lee; Do Young Kim; Hye Won Lee; Su Jong Yu; Young Youn Cho; Jeong Won Jang; Byoung Kuk Jang; Chang Wook Kim; Hee Yeon Kim; Hana Park; Hyo Jung Cho; Bumhee Park; Soon Sun Kim; Jae Youn Cheong Journal: Gut Liver Date: 2021-05-15 Impact factor: 4.519